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Abstract. Angiotensin-converting enzyme (ACE) inhibitors
have been shown to reduce morbidity and mortality in pa-
tients with heart failure due to systolic left ventricular
dysfunction and are indicated in all patients unless contra-
indicated or not tolerated. Despite their ef~cacy, a rela-
tively large percentage of patients in whom these agents are
indicated do not receive them, and the patients who do are
often given doses less than those shown to be effective in
the major morbidity–mortality trials. The failure to use
ACE inhibitors appears to be in large part due to their
perceived side effects, many of which are related to bra-
dykinin accumulation. The introduction of angiotensin II
antagonists such as losartan provides an opportunity to
block the effect of angiotensin II without many of the bra-
dykinin-mediated side effects. Emerging data suggest that
losartan may have an advantage compared to ACE inhibi-
tors in reducing mortality, which appears to be due primar-
ily to a reduction in sudden cardiac death. The potential
mechanisms whereby an angiotensin II antagonist might
reduce mortality in comparison to an ACE inhibitor include
1) a possible direct antiarrhythmic effect of the antagonist,
2) the fact that bradykinin, which may promote ventricular
~brillation by causing the prejunctional release of norepi-
nephrine from sympathetic neurons, does not accumulate
with use of angiotensin II antagonists as opposed to ACE
inhibitors, 3) blockade of effects of angiotensin II produced
in the vascular wall and myocardium by non-ACE-depend-
ent mechanisms, and 4) the fact that angiotensin II antago-
nists increase angiotensin II levels, which may stimulate
angiotensin II type 2 and/or other angiotensin receptors
with bene~cial effects. Large-scale clinical trials are cur-
rently under way comparing the effectiveness of angioten-
sin II antagonists alone and in combination with ACE in-
hibitors to ACE inhibitors alone in reducing total mortality.
These trials will clearly establish whether angiotensin II
antagonists are superior to ACE inhibitors in reducing mor-
tality in patients with heart failure due to systolic left
ventricular dysfunction, as has been observed with losartan
versus captopril in the ELITE study.
ACE inhibitors have been found to be effective and/or
are indicated in the control of hypertension [1], in the
progression of renal dysfunction in patients with type
1 diabetes mellitus and proteinuria [2],  in reducing
morbidity and mortality post-myocardial infarction [3],
and in patients with heart failure due to systolic left
ventricular dysfunction [4]. Their use, however, has
been limited by side effects such as angioedema, cough,
~rst-dose hypotension, renal dysfunction, rash, and
taste disturbances [5,6]. These side effects are in part
related to ACE inhibitor-induced prevention of brady-
kinin degradation and/or to speci~c properties of indi-
vidual ACE inhibitors [6]. Perceptions as to a rela-
tively high incidence of side effects, especially in the
elderly, women,  and  Asians,  have led in  part  to an
underuse of these agents, even where the evidence for
their bene~t—as in heart failure due to systolic left
ventricular dysfunction, where evidence is based upon
prospective, double-blind, randomized trials in many
thousands of patients—is overwhelming [7]. For exam-
ple, in elderly patients with heart failure, it is esti-
mated that ACE inhibitors are used in only half of the
patients in whom they are indicated [8]. When used,
ACE inhibitors are often used at doses considerably
lower than  those shown to be effective in reducing
morbidity and mortality [9]. The introduction of selec-
tive angiotensin II antagonists, such as losartan, which
have excellent tolerability [10] provides an opportunity
to prevent the detrimental effects of angiotensin II on
the cardiovascular system without many of the ACE
inhibitor-related side effects. Should angiotensin II an-
tagonists prove to be at least equally ef~cacious as an
ACE inhibitor in some or all of  the indications for
which they are currently used, they would represent a
major public health bene~t, since they would be ex-
pected to be better tolerated and therefore used in a
greater percentage of patients at effective doses, with
a consequent reduction in morbidity, mortality, and
long-term costs.
The most extensive evidence for a bene~cial effect of
angiotensin II antagonists in humans has been found in
hypertension studies. Angiotensin II antagonists have
been shown to be effective in reducing systolic and dia-
stolic blood pressure but with a lower incidence of side
effects commonly seen with other classes of antihyper-
tensive agents [11,12]. Angiotensin II antagonists have
also been shown to be effective in preventing myocar-
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dial hypertrophy in experimental animals [13] and in
humans [14]. The prevention of myocardial hypertro-
phy is of particular importance, since myocardial hy-
pertrophy has been shown to be associated with an
increase in the risk of death [15]. Long-term prospec-
tive studies such as the Losartan Hypertensive Sur-
vival Study and LIFE (Losartan Intervention For
Endpoint Reduction in  Hypertension) are currently
under way to determine the effect of angiotensin II
antagonists in patients with hypertension and left ven-
tricular hypertrophy on cardiovascular events, includ-
ing stroke, nonfatal myocardial infarction, and death
[16]. The evidence for the effectiveness of angiotensin
II antagonists in patients with heart failure due to sys-
tolic left ventricular dysfunction, although less exten-
sive than the evidence for hypertension, is encouraging
[17]. This article will review the emerging evidence and
potential mechanisms for a bene~cial effect of an
angiotensin II antagonist in patients with heart failure
due to systolic left ventricular dysfunction.
The Effect of Angiotensin II Receptor
Blocking Agents on Hemodynamics
and Neurohormonal Activation in
Patients with Heart Failure
In patients with New York Heart Association (NYHA)
class III–IV heart failure due to systolic left ventricular
dysfunction, losartan reduced mean arterial pressure
and systemic vascular resistance without an increase in
heart rate [18]. These changes were accomplished by a
compensatory increase in angiotensin II concentration
and plasma renin activity and a decrease in plasma al-
dosterone. Dickstein et al. [19] have studied the effect
of losartan in patients with NYHA class III–IV heart
failure due to systolic left ventricular dysfunction and
have found a signi~cant improvement in left ventricu-
lar ejection fraction at a dose of 50 mg qd after 8 weeks,
whereas there was no signi~cant improvement in left
ventricular ejection fraction in patients randomized to
enalapril 20 mg qd. Both losartan and enalapril were,
however, equally effective in improving exercise per-
formance, clinical status, and neurohormonal activa-
tion, including norepinephrine and n-terminal atrial na-
triuretic factor.
Effect of Angiotensin II Receptor
Blocking Agents on Exercise
Performance in Patients with
Heart Failure
The effect of angiotensin II antagonists, such as losar-
tan, on exercise performance in patients with heart
failure has been examined in placebo as well as in ACE
inhibitor controlled trials [20,21]. In placebo-controlled
trials of losartan, both in the United States and inter-
nationally, no signi~cant bene~t of losartan could be
detected either by treadmill testing or by a 6-minute
walk test after 12 weeks of therapy. Of note, however,
is the ~nding in a meta-analysis of these two studies
that patients randomized to losartan had a signi~cant
reduction in hospitalization for heart failure and death
in comparison to placebo [21].
The Effect of an Angiotensin II
Receptor Blocking Agent on Mortality
in Patients with Heart Failure
The losartan heart failure study in the elderly, ELITE
(Evaluation of Losartan in the Elderly) [22], compared
the effect of the angiotensin II antagonist losartan to
the ACE inhibitor captopril in 722 elderly patients with
symptomatic  heart failure (NYHA class II–IV) and
systolic dysfunction (left ventricular ejection fraction #
40%) to determine the tolerability and clinical outcomes
(morbidity/mortality) of these two approaches to block
the renin–angiotensin–aldosterone system. Although
losartan did not demonstrate a signi~cant advantage
with regard to the occurrence of persistent renal dys-
function (the primary endpoint), it was signi~cantly
better tolerated than captopril, with fewer discontinu-
ations due to study drug intolerance. There was a simi-
lar effect in preventing the progression of hospitaliza-
tion for heart failure in both losartan-and captopril-
treated patients, as well as similar effects on improve-
ment in NYHA functional class. In contrast, there was
a signi~cant reduction in all-cause mortality, mainly due
to reduction in sudden cardiac death, in those random-
ized to losartan. These effects of losartan on all-cause
mortality were relatively similar across all subgroups
except for women, who composed less than one third of
patients. The effects of losartan on mortality in women
is essentially similar to captopril and will need to be
reevaluated in a larger prospective randomized study
in which total mortality is the primary endpoint.
The observed mortality bene~t of losartan in symp-
tomatic heart failure patients in ELITE has been fur-
ther established in a meta-analysis of all prospective,
randomized, double-blind losartan trials in patients
with heart failure comprising 1894 patients of whom
740 received control therapy (274 placebo, 96 enalapril,
and 370 captopril) and 1154 patients who received lo-
sartan. The incidence of death in the control group was
6.35% compared to 3.12% in losartan-treated patients;
the odds of dying in the control group were 1.98-Fold
greater than in the  losartan group (95%  con~dence
interval 1.24–3.17)[17].
The potential bene~ts of losartan on mortality in pa-
tients with systolic left ventricular dysfunction are be-
ing further studied in the Losartan Heart Failure Sur-
vival Study, ELITE II, in which patients with NYHA
class II–IV heart failure and systolic left ventricular
dysfunction (LVEF # 40%) who are ACE-inhibitor na-
ive are being randomized to a strategy of an ACE in-
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hibitor (captopril 50 mg three times daily) or to losartan
50 mg once daily, and followed to a total of 406 deaths.
The angiotensin II antagonist valsartan is also under-
going evaluation in a large-scale, 4000-patient  mor-
tality trial (VALHeFT) in patients with systolic left
ventricular dysfunction and NYHA class II–IV heart
failure [23]. In contrast  to  the  ELITE II Losartan
Heart Failure Survival Study, where losartan is being
compared to an ACE inhibitor (captopril), patients in
VALHeFT are being randomized to valsartan 160 mg
bid or placebo on a background of ACE inhibitors. The
potential mechanisms whereby an angiotensin II an-
tagonist might exert a bene~cial effect on mortality in
comparison to an ACE inhibitor are of importance both
for our understanding of the pathophysiology of heart
failure and for the design of future clinical trials and
therapeutic strategies.
Potential Mechanisms for the
Bene~cial Effects on Total Mortality
and Sudden Cardiac Death of an
Angiotensin II Antagonist Compared
to an ACE Inhibitor in Patients with
Systolic Left Ventricular Dysfunction
Direct antiarrhythmic effect
ACE inhibitors have not been shown to have a direct
antiarrhythmic effect [24]. Their effect on sudden car-
diac death is also uncertain. Pahor et al. [24] have re-
viewed the major ACE inhibitor trials in patients with
heart failure. They found three studies in which ACE
inhibitors were effective in reducing sudden cardiac
death, while in ~ve others there was no effect. In a re-
cent study, Binkley et al. [25] noted that ACE inhibitors
but not the angiotensin II antagonist losartan restored
autonomic function as assessed by spectral analysis of
heart-rate variability on 24-hour ambulatory ECG
monitoring. ACE inhibitors failed, however, to restore
the abnormal diurnal pattern of autonomic activity in
patients with heart failure [26]. They attribute the fail-
ure of ACE inhibitors in reducing sudden cardiac death
to the inability of these agents to restore the abnormal
diurnal variation in autonomic balance to normal [26].
The role of angiotensin II antagonists on ventricular
arrhythmias is uncertain. Thomas et al. [27] using an
isolated guinea pig model with simulated ischemia and
early reperfusion, have suggested that losartan has an
antiarrhythmic effect by attenuating the prolongation
of transmural conduction times. This antiarrhythmic
effect appeared to be independent of losartan’s effect
as an angiotensin II antagonist. However, further stud-
ies in  intact conscious  animals  and man,  as  well  as
comparative studies with other angiotensin II antago-
nists, will be required to determine the importance of
this effect and the potential for losartan and/or other
angiotensin II antagonists to reduce ventricular ar-
rhythmias.
Effect of activation and blockade of the
renin–angiotensin–aldosterone system
Activation of the renin–angiotensin–aldosterone sys-
tem, with a resultant increase in angiotensin II, has a
number of potential adverse effects in patients with
systolic left ventricular dysfunction. Although plasma
levels of angiotensin II may not be elevated, or only
moderately elevated, in patients with systolic left ven-
tricular dysfunction, it has been shown that tissue lev-
els, at least in animals with myocardial damage, are
signi~cantly elevated [28]. Increased plasma levels of
angiotensin II cause increased vascular resistance in
both the coronary and peripheral vasculature [29]. In-
creased plasma and/or tissue levels of angiotensin II
may also activate various growth factors, cytokines,
and oxidases, with a resultant release of oxygen free
radicals within the vascular wall, and may lead to en-
dothelial dysfunction, vasoconstriction, increased sen-
sitivity of the vascular wall to angiotensin II and other
endothelial-mediated vasodilators [30–32], and hence a
vicious cycle leading to atherosclerosis and its conse-
quences. Local angiotensin II production as a conse-
quence of myocardial injury can also lead to myocardial
hypertrophy and ~brosis [33], which could in itself pre-
dispose to sudden cardiac death [34]. While in the nor-
mal heart angiotensin II has been shown to have a mild
positive inotropic effect, in the failing heart it exerts a
negative inotropic effect that can be reversed by losar-
tan [35]. In addition to its adverse effects on the myo-
cardium and vascular wall, angiotensin II causes the
release of norepinephrine from sympathetic nerve end-
ings and decreases myocardial norepinephrine uptake
[36], which in conjunction with decreased ventricular
function and myocardial hypertrophy and/or scarring
could predispose to sudden cardiac death. Many of the
known physiologic and/or pathophysiologically impor-
tant effects of angiotensin II have been shown to be
due to stimulation of the angiotensin II type 1 (AT1)
receptor [37]. The AT1 receptor is coupled to G proteins
and involves protein lipase C. adenylate cyclase, and
the release of intracellular calcium [38]. Thus, in-
creased plasma and/or tissue levels of angiotensin II
with stimulation of the AT1 receptor could be expected
to have an adverse effect on the morbidity and mortal-
ity of patients with heart failure due to systolic left
ventricular dysfunction.
Bradykinin generation
ACE inhibitors and angiotensin II antagonists block
the effect of angiotensin II by inhibiting its formation
or by blocking its effect on the AT1 receptor. However,
unlike ACE inhibitors, angiotensin II antagonists do
not block the degradation of bradykinin [39], which has
a number of potentially bene~cial as well as adverse
effects [40].
Bradykinin possess several bene~cial effects and is
thought to be cardioprotective [40]. By stimulating bra-
dykinin B2 receptors, its triggers the release of nitric
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oxide and prostacyclin from the vascular wall [41,42],
which may account for the bene~cial effects of ACE
inhibitors  in improving endothelial dysfunction  [43].
Bradykinin has also been shown to reduce myocardial
oxygen demands [44] and to have an important effect on
ventricular hypertrophy and ~brosis [45]. Bradykinin
also reduces the incidence of ventricular premature
beats and ventricular tachycardia in dogs with myocar-
dial ischemia [46]. Blockade of bradykinin B2 receptors
by HOE-140 attenuates this antiarrhythmic effect of
bradykinin [47]. Exogenous bradykinin has also been
shown to reduce epinephrine-induced arrhythmias by a
mechanism involving the release of NO and pro-
staglandin [48]. ACE inhibitors have also been shown to
reduce experimental infarct size and to prevent ven-
tricular remodeling by a bradykinin-mediated effect,
since these bene~ts can be eliminated by the admini-
stration of the bradykinin B2 receptor antagonist HOE-
140 [49,50]. The bene~cial effect of ACE inhibitors at
subhemodynamic doses in preventing ventricular hy-
pertrophy and improving myocardial metabolism and
infarct size in experimental animals has been attributed
in part to ACE inhibitor-induced bradykinin accumula-
tion [51]. These experiments raise the possibility that
ACE inhibitors, because of their effects on preventing
the degradation of bradykinin, may be more advan-
tageous than angiotensin II antagonists in preventing
progressive heart failure and death.
Considerable controversy persists, however, re-
garding the bene~cial effects of ACE inhibitor-induced
bradykinin accumulation after myocardial infarction
[52–56]. In some models of experimental myocardial
infarction, angiotensin II antagonists have been shown
to be equal or superior to an ACE inhibitor in prevent-
ing ventricular remodeling and prolonging survival af-
ter experimental myocardial infarction. In a rat model
of high-output failure, an ACE inhibitor and an an-
giotensin II antagonist have been equally effective in
preventing ventricular hypertrophy and hemodynamic
deterioration [56]. The ~nding that the bene~cial ef-
fects of an angiotensin II antagonist may also be ne-
gated in part by the bradykinin B2 receptor antagonist
HOE-140 [57] further complicates speculation concern-
ing the differentiation of the therapeutic effects of an-
giotensin II receptor blockade from those of ACE in-
hibition. The situation may be further complicated by
the suggestion that tissue levels of bradykinin may be
more important than plasma levels in producing a
cardioprotective effect [58]. Plasma kinins have been
found to be released from the heart during myocardial
ischemia in experimental animals [59–61] and in hu-
mans [62–64]. Duncan et al. [58] found, however, that
although an ACE inhibitor could increase myocardial
tissue and circulating bradykinin levels in normal rats,
a similar increase in animals with myocardial infarction
could not be demonstrated. They suggest that the fail-
ure of ACE inhibitors to increase myocardial tissue
levels of bradykinin in animals with myocardial in-
farction may have been the result of the induction of
other enzymes, such as aminopeptidase and neutral
endopeptidase. They attribute the bene~cial effect of
an ACE inhibitor on ventricular hypertrophy and re-
modeling in their model to a reduction in angiotensin II
formation rather than to bradykinin accumulation.
It should also be pointed out that bradykinin is an
endothelial-mediated vasodilator [65]. Endothelial dys-
function is common in patients who require ACE in-
hibitors  for  disorders such  as  hypertension, athero-
sclerosis, and heart failure, especially the elderly [66].
In patients with coronary artery disease, bradykinin
administered directly into a coronary artery failed to
produce vasodilatation, whereas the endothelial-inde-
pendent vasodilator nitroglycerin produced signi~cant
vasodilation [67]. In a study in dogs, an angiotensin II
antagonist has in fact been found to be a more effective
coronary vasodilator than an ACE inhibitor [68]. The
bene~cial effects of bradykinin, if present, may be less
evident in elderly than in young patients. Experimen-
tal studies show that bradykinin has less of an effect on
vasodilatation in the elderly than in the young [69,70]
and may in fact cause vasoconstriction in the elderly
[69].
The adverse effects of bradykinin [71] are well
known and include an increase in vascular permeability
that may contribute to ACE inhibitor-induced angio-
edema, cough, and under certain circumstances, de-
crease in glomerular in~ltration rate [72]. Less appre-
ciated, however, is the fact that bradykinin causes the
release of norepinephrine from prejunctional sympa-
thetic neurons [73]. Direct epicardial application of bra-
dykinin results in a signi~cant increase in renal sympa-
thetic nerve activity [74]. Schwieler et al. compared the
effects of norepinephrine over_ow of the ACE inhibi-
tor benazeprilat vs. losartan in a canine in situ gracilis
muscle preparation [75]. Losartan signi~cantly re-
duced norepinephrine over_ow by 14%, whereas the
ACE inhibitor signi~cantly increased norepinephrine
over_ow by 12%. During ACE inhibition, the brady-
kinin B2 receptor antagonist HOE-140 signi~cantly re-
duced norepinephrine over_ow. In a model of global
ischemia in isolated guinea pig hearts, Hatta et al. [76]
observed an increase in norepinephrine over_ow and
ventricular ~brillation. Administration of the B2 recep-
tor antagonist HOE-140 alone had no signi~cant effect
on norepinephrine release or on the duration of ven-
tricular ~brillation in this model. The administration of
enalapril, however, caused a further increase in no-
repinephrine over_ow and a prolongation of the epi-
sodes of ventricular ~brillation. This effect could be
prevented by HOE-140. Administration of an angio-
tensin II antagonist decreased both norepinephrine
over_ow and the incidence of ventricular ~brillation.
There was a further decrease in norepinephrine over-
_ow and in the incidence of ventricular ~brillation
when HOE-140 was administered in addition to the
angiotensin II antagonist. The authors suggest that in
situations such as myocardial ischemia, angiotensin II
may be locally produced in concentrations suf~cient to
224 Pitt
enhance exocytotic and carrier-mediated norepineph-
rine release by stimulation of AT1 receptors, resulting
in an increase in ventricular ~brillation. Bradykinin
appears to release norepinephrine and to increase ven-
tricular arrhythmias only when its half-life is pro-
longed, e.g., by an ACE-inhibitor, and/or when the ef-
fects of angiotensin II are suppressed [76]. The ~nding
that ACE inhibitors not only prolong the half-life of
bradykinin but also prevent bradykinin B2 receptor
internalization and desensitization [77] could also con-
tribute to the potentially adverse effects of ACE in-
hibitor-induced bradykinin accumulation under these
circumstances.
Bradykinin has also been shown to have an impor-
tant interaction with ouabain in causing norepin-
ephrine release [78]. In cultured adrenal chromophil
cells, the combination of ouabain plus bradykinin re-
sults in a signi~cantly greater release of catecholami-
nes than occurs with either agent alone. Bradykinin-in-
duced Ca2 in_ux into adrenal chromophil cells and the
consequent activation of bradykinin B2 receptors is
potentiated by a ouabain-induced Na1–K1 ATPase in-
hibition. Sodium in_ux into the adrenal cells as a result
of bradykinin stimulation is normally balanced by
Na1–K1 ATPase and results in increased intracellular
Na1 accumulation and Ca21 induced catecholamine se-
cretion. In the ELITE Losartan Heart Failure Trial
[22], more than 70% of patients were on digoxin, allow-
ing the postulation that ACE inhibitor bradykinin ac-
cumulation in conjunction with digoxin could lead to
increased norepinephrine release that might offset the
bene~cial effect of ACE inhibitor-induced reduction in
angiotensin II formation. However, angiotensin II an-
tagonists might have a greater effect in blocking no-
repinephrine release in patients both with or without
concomitant digoxin and might thus prevent sudden
cardiac death, since they are not associated with in-
creased bradykinin formation. While this hypothesis is
attractive, it should be pointed out that in the ELITE
Losartan Heart Failure Trial [22], there was no
signi~cant interaction between digoxin and losartan
with respect to mortality.
In addition to causing the release of norepinephrine
from prejunctional sympathetic neurons,  bradykinin
has been shown to release interleukin (IL-1B) and tu-
mor necrosis factor from macrophages [79]. This effect
of bradykinin could also have important negative inot-
ropic effects through cytokine stimulation of inducible
nitric oxide synthase and oxygen free radical produc-
tion.
Thus, the net effect of ACE inhibitor-induced
bradykinin accumulation and therefore the relative ef-
fectiveness of an ACE inhibitor and an angiotensin II
antagonist is dif~cult to predict. The  relative effec-
tiveness of an ACE-inhibitor compared to an angio-
tensin I antagonist may  depend upon  whether nor-
epinephrine over_ow is increased by endogenous
bradykinin or whether bradykinin-induced nitric oxide
or prostaglandin release, or both, protects against
catecholamine-induced arrhythmias. These effects may
vary among species and experimental conditions. The
degree of sympathetic nerve activity, presence or ab-
sence of endothelial dysfunction, presence or absence of
ischemia, cytokine activation, and prostaglandin syn-
thesis is variable and may be critical in determining the
net effect of an ACE inhibitor compared with that of an
angiotensin II antagonist on ventricular arrhythmias
and sudden cardiac death. ACE inhibitors have been
shown to reduce sympathetic nerve activity [80] and
metaiodobenzylgaunidine uptake [81] in patients with
heart failure. The net effect of bradykinin on this effect
is uncertain and may vary depending upon clinical cir-
cumstances. Clearly, only direct comparative studies in
humans, such as the Losartan Heart Failure Survival
Trial, ELITE II, and VALHeFT [23], will determine the
relative bene~ts of ACE inhibitor and angiotensin II
antagonists, and therefore, the potential contribution of
bradykinin to the bene~cial effects of ACE inhibition in




The bene~cial effects of losartan compared to captopril
in reducing total mortality and, in particular, sudden
cardiac death in the ELITE Trial [22] could also be
related to more complete blockade of ACE and non-
ACE-dependent angiotensin II formation during nor-
epinephrine release and/or to other adverse effects of
angiotensin II. Angiotensin II has been shown to be
produced by   both ACE   and non-ACE-dependent
mechanisms such as chymase [82]. ACE inhibitors
block ACE-dependent angiotensin II formation,
whereas angiotensin II antagonists block the effects of
angiotensin II produced by both ACE- and non-ACE-
dependent pathways. Plasma angiotensin II levels are
increased in patients with severe heart failure whose
condition deteriorate despite long-term ACE inhibitor
therapy  at  doses shown to be effective  in  reducing
mortality [83]. ACE inhibitors do not block all the ef-
fects of angiotensin II on human arteries, whereas
losartan or the combination of a chymase inhibitor and
an ACE inhibitor has been shown to be more effective,
suggesting an important role for non-ACE-dependent
angiotensin II formation in human vessels [84,85]. Non-
ACE-dependent angiotensin II formation may also be
important in the human myocardium [86]. The adverse
effects of angiotensin II on myocardial hypertrophy,
~brosis, and contractility in the failing heart could
therefore be blocked more effectively by an angioten-
sin II antagonist, which would block both ACE- and
non-ACE-dependent formation of angiotensin II, than
by an ACE inhibitor, which would block only ACE-de-
pendent formation of angiotensin II. It has been noted
that whereas chymase contributes relatively little to
the level of angiotensin II in blood, it is prevalent in the
interstitium, in the media, and in adventitial regions of
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the vessel wall, where it could have important func-
tional consequences [86]. Of particular interest is the
presence of chymase in human mast cells. Schieffer et
al. [87] has  shown increased chymase expression in
mast cells within the shoulder region of atherosclerotic
coronary plaques in patients with unstable angina pec-
toris. There is a direct correlation between the expres-
sion of chymase in human coronary arteries and LDL
cholesterol [88]. Since mast cells are thought to play an
important role in plaque rupture, it can be postulated
that, in patients with elevated serum cholesterol lev-
els, an angiotensin II antagonist would be more effec-
tive than an ACE inhibitor in preventing plaque rup-
ture. Plaque rupture with subsequent incomplete or
complete thrombosis formation and distal platelet em-
bolization has been suggested to be an important
mechanism in sudden cardiac death [89]. Thus, in the
presence of substantial production of angiotensin II by
non-ACE-dependent mechanisms in the myocardium
and vascular wall, an angiotensin II antagonist would
be expected to exert a more bene~cial effect than an
ACE inhibitor on angiotensin II-mediated norepineph-
rine release as well as on plaque rupture and sudden
cardiac death. Controversy exists, however, concern-
ing the magnitude of non-ACE- dependent angiotensin
II formation in the human myocardium. Further pro-
spective studies must document the importance of this
mechanism in patients with heart failure and systolic
left ventricular dysfunction  from both  ischemic and
nonischemic causes.
Stimulation of angiotensin II type 2 and
other angiotensin receptors
Another possibility relates to the ~nding that an angio-
tensin II antagonist may cause an increase in plasma
angiotensin II levels as well as unopposed stimulation
of angiotensin II type 2 (AT2) and/or other angiotensin
receptors [90]. Stimulation of the angiotensin IV recep-
tor in isolated endothelial cells causes release of plas-
minogen activator inhibitor (PAI-I) [91] and endothelin
that cannot be blocked by an angiotensin II antagonist
[92]. In the intact organism, however, these effects can
be blocked by an angiotensin II antagonist [93,94]. An
important role has been suggested for the AT2 receptor
in myocardial cell growth and apoptosis [95,96]. Stimu-
lation of the AT2 receptor causes the induction of endo-
thelial nitric oxide synthase [97] and the release of NO
[98]. The production of NO by the AT2 receptor could
therefore have important bene~ts on vascular reactiv-
ity, platelet adhesion, and myocardial cell growth. In
contrast, an ACE inhibitor, by blocking the conversion
of angiotensin I to angiotensin II, is less likely to cause
stimulation of the AT2 and/or other angiotensin II re-
ceptors [90]. Accumulating data suggest that AT2 re-
ceptors or the AT2:AT1 receptor ratio, or both, are in-
creased in patients with myocardial hypertrophy [99]
and heart failure [100]. Unopposed stimulation of these
AT2 receptors after blockade of the AT1 receptor has
been suggested to result in local release of nitric oxide
directly or through kinins [101]. Myocardial ~broblasts
have been shown to express AT1 and AT2 receptors
[102,103] as well as speci~c receptors for angiotensin
(1–7) [104]. In cardiomyopathic hamsters with heart
failure, an AT1 receptor antagonist decreases the ex-
tent of interstitial ~brosis by 28% after 20 weeks of
therapy. An AT2 receptor antagonist, in contrast, in-
creased the extent of interstitial ~brosis by 29% [102].
Thus, it would appear that stimulation of AT2 receptors
inhibits collagen formation and prevents myocardial
~brosis during cardiac remodeling. This effect may be
time dependent, since it was seen after 4 weeks of
therapy but not at 20 weeks [102]. Unopposed stimula-
tion of AT2 receptors due to the blockade of the AT1
receptor has been suggested to result in local release
of nitric oxide directly or through kinins [101]. In
bovine pulmonary endothelial cells, angiotensin II in-
duces endothelial nitric oxide synthase (eNOS) [96].
Administration of an AT2 blocking agent prevented the
induction of eNOS, whereas losartan ingiotensin II-in-
duced eNOS, and the combination of losartan and AT2
receptor blocking agent prevented eNOS induction
[96]. Liu et al. [101], in a model of chronic heart failure
due to myocardial infarction in Lewis inbred rats, have
shown that the bene~cial effect of AT1 receptor block-
ade in preventing ventricular remodeling could in part
be blocked by the administration of the bradykinin B2
antagonist HOE-140. Administration of an AT2 recep-
tor blocking agent in conjunction with an AT1 receptor
blocking agent has resulted in the loss of the bene~cial
cardioprotective effects of an AT1 receptor antagonist.
Liu et al. [101] have proposed that blockade of AT1
receptors results in an increase in renin: angiotensin II:
other angiotensins, such as angiotensin (1–7), which
stimulate AT2 (1–7); and/or other receptors. Stimula-
tion of the AT2 and/or other receptors may play an
important role in the bene~cial effect of AT1 receptor
blockade by stimulating the release of NO, kinins,
and/or other autocoids. Lee et al., in rats spontaneously
hypertensive  have shown  that  losartan  signi~cantly
reduced infarct size, the incidence of ventricular ~bril-
lation, and mortality [105]. They attribute this
bene~cial effect of losartan to AT2 receptor stimulation
with release of NO, and prostaglandins [105]. The
bene~cial effects of AT1 receptor blockade on the re-
gression of myocardial hypertrophy has also been
shown to be prevented by the simultaneous admini-
stration of an AT2 receptor blocking agent [108]. Stimu-
lation of the angiotensin (1–7) receptor, in conjunction
with bradykinin, causes vasodilatation as well as the
release of bradykinin and NO from the endothelium
[107,108], which might also contribute to the bene~cial
effects of an AT1 blocking agent. Fernandez et al. [110]
have shown that losartan increases survival in an ani-
mal model with abrupt unilateral carotid artery occlu-
sion. The effect of losartan in this model was, however,
negated by the concomitant administration of an ACE
inhibitor, also suggesting the importance of unopposed
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stimulation of AT2 and possibly other receptors in the
bene~cial effects of AT1 receptor blockade.
Combination Therapy
The potential mechanisms by which an AT1 receptor
blocking agent might reduce mortality and sudden car-
diac death in comparison to an ACE inhibitor in
patients with heart failure due to left ventricular dys-
function are of importance in planning future therapeu-
tic strategies. For example, if an angiotensin II antago-
nist reduces mortality by more complete blockade of
the effects of angiotensin II (whether this blockade is
produced by ACE or non-ACE-dependent mecha-
nisms), with a resultant decrease in myocardial hyper-
trophy, ~brosis, coronary vasoconstriction, and possi-
bly norepinephrine release, then the combination of an
ACE inhibitor and an angiotensin II antagonist such as
that being tested in VALHeFT [23] might be prefer-
able, since it would provide the bene~cial effects of
bradykinin accumulation while more effectively pre-
venting the potential adverse effects of angiotensin II
(whether ACE or non-ACE dependent). The combina-
tion of the ACE inhibitor enalapril 10 mg twice daily
and losartan 50 mg once daily has been compared to
enalapril 10 mg twice daily in the Randomized An-
giotensin Converting Enzyme Angiotensin Receptor
Antagonist Study (RAAS) [111,112]. In this study, the
combination of enalapril and losartan was well toler-
ated in patients with symptomatic heart failure and
systolic left ventricular dysfunction. The combination
resulted in a signi~cant decrease in serum aldosterone
levels in comparison to target-dose enalapril (10 mg
twice daily) and high-dose enalapril (20 mg twice
daily), as well as trend toward more effective suppres-
sion of norepinephrine  in patients with  an elevated
level at baseline (.300 pg/mL). Other studies in pa-
tients with heart failure have shown that combination
therapy with an angiotensin II antagonist, such as
valsartan and an ACE inhibitor, to be more effective in
reducing pulmonary capillary wedge pressure than
monotherapy, with an ACE inhibitor in patients with
heart failure and systolic left ventricular dysfunction
[113,114]. These studies have, however, been too small
and too short in duration to determine the effect of
combination therapy on morbidity and/or mortality. In
a canine model induced by atrial pacing [115,116] the
combination of valsartan and  an ACE inhibitor has
been found to be signi~cantly better than valsartan
alone in preventing ventricular remodeling and some
of  the consequences of  heart  failure. The effects  of
angiotensin II antagonists on ventricular remodeling
may, however, under certain circumstances be less im-
portant in improving survival than their effects on
coronary hemodynamics, nitric oxide, and/or norepin-
ephrine release. For example, in a rat model of myo-
cardial infarction, the angiotensin II antagonist irbe-
sartan improved survival in comparison to control
animals without irbesartan but had relatively little ef-
fect in preventing ventricular remodeling [117]. In the
ELITE Trial [22], losartan appeared equally effective
as captopril in  preventing progressive heart failure
and ventricular remodeling [118] but was signi~cantly
better in  improving survival [22]. Regardless  of its
effectiveness in preventing ventricular remodeling,
the risk–bene~t and cost–bene~t effects of combination
therapy will need to be prospectively investigated in
comparison to monotherapy with losartan and other
angiotensin II antagonists with regard to survival. One
of the major bene~ts of angiotensin II antagonists in
patients with heart failure is the tolerability of these
agents in comparison to ACE inhibitors [119]. A major
reason that ACE inhibitors  have failed  to  be  more
widely used in patients with heart failure is the per-
ceived side effects of these agents. In a study of pa-
tients with hypertension who were not controlled with
the ACE inhibitor lisinopril, the addition of losartan
resulted in better blood pressure control but also a 20%
increase in the incidence of cough [120]. Thus, the
bene~t of combination therapy will need to be carefully
investigated with regard to its tolerability and effec-
tiveness in all patients with heart failure due to systolic
left ventricular dysfunction, rather than in only the
subset of patients who tolerate an ACE inhibitor. How-
ever, if losartan reduces mortality in comparison to
captopril in ELITE II due to an anti~brillatory effect,
independent of its effect on AT1 receptor blockade, or
perhaps more likely due to a lesser degree of
bradykinin accumulation and norepinephrine release
or a greater degree of unopposed stimulation of AT1
and/or other angiotensin II receptors [90] with sub-
sequent release of NO and/or prostaglandins, the com-
bination of an ACE inhibitor and an angiotensin II
antagonist might not be as effective as an angiotensin
II antagonist alone.
Conclusions
The results of the evaluation of Losartan in the Elderly
(ELITE) heart failure study [22] are clearly an impor-
tant stimulus for further basic and clinical investiga-
tion into the mechanisms responsible for cardiovascu-
lar death in patients with heart failure due to systolic
left ventricular dysfunction. Whether these effects on
sudden cardiac death are speci~c to losartan or to other
angiotensin II antagonists as well will, however, re-
quire  the results of  the ELITE II Losartan  Heart
Failure Study and other prospective randomized trials
such as VALHeFT [23] to determine their clinical role
in comparison to ACE inhibitors for the therapy of
patients with heart failure due to systolic left ventricu-
lar dysfunction. The suggestion that the angiotensin II
antagonist candesartan alone or in combination with
enalapril does not have as bene~cial an effect as enala-
pril alone in patients with heart failure [121] suggests
that we cannot extrapolate the bene~cial effects of
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losartan in ELITE [22] to all angiotensin II antago-
nists. Likewise, it may be prudent to await the results
of further large-scale randomized trials such as ELITE
II and VALHeFT [23] before routinely using any an-
giotensin II antagonist, including losartan, alone or in
combination with an ACE-inhibitor in patients with
heart failure in whom an ACE inhibitor is indicated
and well tolerated.
It should, however, be pointed out that losartan, but
not candesartan, inhibits vascular thromboxane A2/
prostaglandin H2 receptors [123]. These receptors have
been associated with arachidonic acid-induced sudden
cardiac death [124]. In spontaneously hypertensive
rats, Li et al. have found that losartan, but not can-
desartan, prevents thromboxane A2/prostaglandin H2-
induced platelet aggregation and vasoconstriction
[125]. Losartan, but not candesartan, augments acetyl-
choline-induced nitric oxide-dependent vasodilatation
and abolishes endothelium-derived, constricting factor-
mediated vasoconstriction [125]. The dose of losartan
shown to be bene~cial in these experiments may, how-
ever, be beyond the pharmacologic range. These ex-
periments will need to be con~rmed in humans at phar-
macologic doses before we can attribute any potential
difference between losartan and candesartan or other
angiotensin II antagonists to this mechanism.
Perhaps  the most important lesson from ELITE
[22] and other studies of the renin–angiotensin–aldos-
terone system is that while experimental studies are of
importance in determining pathophysiologically impor-
tant mechanisms, the relative importance of any indi-
vidual mechanism  may be  species and/or  model de-
pendent. Our current understanding of mechanisms,
especially with regard to the renin–angiotensin–aldos-
terone system, is as yet incomplete. Studies of speci~c
receptor-mediated mechanisms and/or speci~c recep-
tor antagonists, while suggestive, may not be conclu-
sive due to positive and/or negative neurohumoral
feedback loops, cross-talk between receptors,  inter-
nalization and desensitization of receptors, and/or un-
coupling of receptors from their effector signaling
pathways. While the results of large-scale clinical trials
may not necessarily provide insight into pathophysi-
ologic mechanisms, they do provide insight into the net
effect of therapeutic strategies, at least under the par-
ticular circumstances of the clinical trial. Only by well-
designed, large-scale, prospectively randomized clini-
cal trials and smaller-scale preclinical and clinical
studies designed to investigate speci~c mechanisms
can we hope to increase our understanding of disease
processes and to develop new and more effective thera-
peutic strategies.
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